Matinas BioPharma Holdings Inc MTNB:NYSE American

Last Price$0.79AMEX Previous Close - Last Trade as of 8:00PM ET 7/01/22

Today's Change0.00(0.00%)
Bid (Size)$0.80 (1)
Ask (Size)$0.81 (6)
Day Low / High$0.78 - 0.81
Volume155.4 K
  • Latest Stories
  • Commentary and Analysis
Sector Update: Health Care
3:51PM ET 4/11/2022 MT Newswires

Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 1.6% while the SPDR Health Care Select Sector ETF (XLV) was...

Sector Update: Health Care Stocks Decline Premarket Monday
9:17AM ET 4/11/2022 MT Newswires

Health care stocks were declining premarket Monday. The Health Care SPDR (XLV) was down 0.22% and the iShares NASDAQ Biotechnology Index (IBB) was recently...

BioNTech, Matinas BioPharma Sign Exclusive Research Deal on Lipid Nanocrystal Technology
7:21AM ET 4/11/2022 MT Newswires

BioNTech SE (BNTX) and Matinas BioPharma Holdings, Inc. (MTNB) said Monday that they have signed an exclusive research agreement to evaluate the...

Matinas BioPharma Holdings Posts Flat Q4 Net Loss
6:55AM ET 3/08/2022 MT Newswires

Matinas BioPharma Holdings (MTNB) reported a Q4 net loss Tuesday of $0.03 per diluted share, unchanged from a year earlier. Analysts polled by Capital IQ...

Matinas BioPharma Says Data Monitoring Panel Backs Continuation of Meningitis Trial to Final Patient Cohort
7:35AM ET 12/16/2021 MT Newswires

Matinas BioPharma (MTNB) said Thursday the data safety monitoring board recommended the continuation of its cryptococcal meningitis trial into the fourth...

Matinas BioPharma Holdings Names Chief Business Officer
6:42AM ET 12/06/2021 MT Newswires

Matinas BioPharma Holdings (MTNB) said Monday it appointed Thomas Hoover to the newly created role of chief business officer. Hoover's most recent post...

Matinas BioPharma Doses First Patient in Phase 1 Study of Antibiotic Drug Candidate
11:00AM ET 10/21/2021 MT Newswires

Matinas BioPharma Holdings (MTNB) said Thursday it has dosed the first patient in an early-stage study of its oral aminoglycoside antibiotic drug...

Matinas Says MAT2203 Exceeds Primary Endpoint Threshold of Fungal Clearance in Phase 2 Trial in Cryptococcal Meningitis
10:32AM ET 9/13/2021 MT Newswires

Matinas BioPharma Holdings (MTNB) said Monday that MAT2203 exceeded the primary endpoint threshold target of fungal clearance in the second cohort of a...

Matinas BioPharma Secures US Patent on MAT2203 to Treat or Prevent Cryptococcus Infections
10:14AM ET 8/16/2021 MT Newswires

Matinas BioPharma Holdings (MTNB) said Monday that the US Patent and Trademark Office has issued a notice of allowance for a US patent application covering...